Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.55 +0.45 (+1.64%)
Streaming Delayed Price Updated: 11:33 AM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines
As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of... 
Via Finterra
Topics Economy
News headline image
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? ↗
Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology. 
Via Stocktwits
Topics Earnings
News headline image
2 Reasons to Like ZTS (and 1 Not So Much)
Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the... 
Via StockStory
Topics Stocks
News headline image
OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗
OPKO Health (OPK) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.
Even amid volatility, Pfizer keeps rewarding shareholders year after year. 
Via Barchart.com
Topics Artificial Intelligence
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
Via Finterra
Topics Economy
News headline image
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of... 
Via StockStory
News headline image
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash ↗
Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly. 
Via Stocktwits
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
Eli Lilly has seen revenue and earnings soar in recent years. 
Via The Motley Fool
News headline image
Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment ↗
Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation. 
Via Benzinga
News headline image
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment ↗
Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset. 
Via Benzinga
News headline image
Pfizer Stock: Is PFE Underperforming the Healthcare Sector?
Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects 
Via Barchart.com
Topics ETFs Intellectual Property World Trade
News headline image
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗
According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income ↗
Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive. 
Via The Motley Fool
Topics Intellectual Property
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
Via Investor Brand Network
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release... 
Via FinancialNewsMedia
News headline image
Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a... 
Via MarketMinute
News headline image
Kenvue Defies Market Headwinds with Q4 Earnings Beat as Kimberly-Clark Merger Looms
In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just... 
Via MarketMinute
Topics Earnings Economy World Trade
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
News headline image
My 5 Favorite Dividend Stocks to Buy Right Now ↗
There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.